Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital upgrades Convatec to 'outperform'

(Sharecast News) - RBC Capital Markets upgraded Convatec on Thursday to 'outperform' from 'sector perform' as it said the recent share price reaction was likely overdone and the current price is a buying opportunity ahead of solid underlying top line growth and mid-term margin development. The bank noted the shares are down 20% since June peaks, reflecting news flow around the proposed reimbursement changes in the US.

"The shares now trade on 16.5x 2026E P/ E, towards the lower end of the 5-year range and below the 3-year average valuation premium to the peer group," it said.

"We adjust our forecasts for H1 results and our updated view on 2026 and 2027, as well as the recently announced $300m share buy-back programme, roll forwards our valuation and move our price target to 315p (from 320p)," it said.

"With risk-reward skewed clearly to the upside, further clarity on these reimbursement changes could prove a positive catalyst (expected Q4 2025)."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.